Metformin decreases IL‐22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Epidemiological, preclinical and cellular studies in the last 5 years have shown that metformin exerts anti‐tumoral properties, but its mode of action in cancer remains unclear. Here, we investigated the effects of metformin on a mouse hepatocellular carcinoma (HCC) model and tumor‐associated T cell immune responses. Oral metformin administration led to a significant reduction of tumor growth, which was accompanied by decreased interleukin‐22 (IL‐22). Meanwhile, IL‐22‐induced STAT3 phosphorylation and upregulation of downstream genes Bcl‐2 and cyclin D1 were inhibited by metformin. At the cellular level, metformin attenuated Th1‐ and Th17‐derived IL‐22 production. Furthermore, metformin inhibited de novo generation of Th1 and Th17 cells from naive CD4+ cells. These observations were further supported by the fact that metformin treatment inhibited CD3/CD28‐induced IFN‐γ and IL‐17A expression along with the transcription factors that drive their expression (T‐bet [Th1] and ROR‐γt [Th17], respectively). The effects of metformin on T cell differentiation were mediated by downregulated STAT3 and STAT4 phosphorylation via the AMP‐activated kinase‐mammalian target of rapamycin complex 1 pathway. Notably, metformin led to a reduction in glucose transporter Glut1 expression, resulting in less glucose uptake, which is critical to regulate CD4+ T cell fate. Taken together, these findings provide evidence for the growth‐inhibitory and immune‐modulatory effects of metformin in HCC and thus, broaden our understanding about the action of metformin in liver cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 1×
“ciation of mTOR with the adaptor proteins raptor and rictor, respectively.(39) They exert disparate effects on effector T cell”
BackgroundLiang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330
Michalek, R. D., Gerriets, V. A., Jacobs, S. R., Macintyre, A. N., MacIver, N. J., Mason, E. F., Sullivan, S. A., Nichols, A. G., & Rathmell, J. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003613 · Cited by 2,091
Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells
Duhen, T., Geiger, R., Jarrossay, D., Lanzavecchia, A., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1767 · Cited by 1,079
Trifari, S., Kaplan, C. D., Tran, E. H., Crellin, N. K., & Spits, H. (2009) · Nature Immunology · doi:10.1038/ni.1770 · Cited by 1,021
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Wieman, H. L., Wofford, J. A., & Rathmell, J. C. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-07-0593 · Cited by 593
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2010) · Diabetes Care · doi:10.2337/dc09-1791 · Cited by 466
Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M., et al. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.007 · Cited by 402
Cited by
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Cha, J.-H., Yang, W.-H., Xia, W., Wei, Y., Chan, L.-C., Lim, S.-O., Li, C.-W., Kim, T., Chang, S.-S., Lee, H.-H., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.030 · Cited by 773
Metabolic pathways in T cell activation and lineage differentiation
Almeida, L., Lochner, M., Berod, L., & Sparwasser, T. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.10.009 · Cited by 475
Repurposing metformin for the prevention of cancer and cancer recurrence
Heckman-Stoddard, B. M., DeCensi, A., Sahasrabuddhe, V. V., & Ford, L. G. (2017) · Diabetologia · doi:10.1007/s00125-017-4372-6 · Cited by 297
In silico clinical trials: how computer simulation will transform the biomedical industry
Viceconti, M., Henney, A., & Morley-Fletcher, E. (2016) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20161408 · Cited by 289
Li, L., Wang, L., Li, J., Fan, Z., Yang, L., Zhang, Z., Zhang, C., Yue, D., Qin, G., Zhang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2460 · Cited by 266
Metadata
- Authors
- Zhao, D., Long, X., Lu, T., Wang, T., Zhang, W., Liu, Y., Cui, X., Dai, H., Xue, F., & Xia, Q.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2014-11-21
- Volume
- 136
- Issue
- 11
- Pages
- 2556-2565
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1901407464
- Cited by
- 77
- References
- 9
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.